STRASBOURG, France, October 10 /PRNewswire-FirstCall/ -- Transgene S.A. announces that cash, cash equivalents and short term investments totaled EUR 119 million at September 30, 2007 compared to EUR 114.3 million at June 30, 2007 (unaudited figures, IAS/IFRS).
For the first nine months of 2007, cash, cash equivalents and short term investments increased by EUR 98.7 million. This was mainly due to payments received from the partnership agreement with Roche (EUR 23 million), the capital increase carried out in June and July 2007 (net proceeds: EUR 95.3 million) and cash expenditures of EUR 19.6 million.
About Transgene:
Transgene is a France-based biopharmaceutical company dedicated to the development of therapeutic vaccines and immunotherapeutic products in oncology and infectious diseases. The company has one product which has completed Phase II trials (TG4001/R3484), two compounds in Phase II trials (TG4010 and TG1042) and one compound in Phase I studies (TG4040). Transgene has concluded a strategic partnership agreement with Roche for the development of its TG4001/R3484 therapeutic vaccine to treat HPV-mediated diseases. Transgene has bio-manufacturing capacities for viral-based vectors and technologies available for out-licensing. Additional information about Transgene is available on the Internet at http://www.transgene.fr.
CONTACT: Investor contacts: Transgene, Philippe Poncet, Chief Financial
Officer, Phone: +33-3-88-27-91-21, Press contacts: Capital MS&L, Mary
Clark, Anna Mitchell, Phone: +44-20-7307-5330, anna.mitchell@capitalmsl.com
